Drugs / GEN0101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02502994 | May 2015 → Dec 2016 | castration-resistant prostate carcinoma | Norio Nonomura | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03818893 | Mar 2019 → Dec 2021 | melanoma | Osaka University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2008-10-28 | AnGes, Inc. | Results GEN0101のホルモン抵抗性前立腺がんに対する治療効果を確認 －第67回 日本癌学会学術総会で動物試験結果を発表－ anges.co.jp ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-09-22 | AnGes, Inc. | 当社子会社ジェノミディアによる抗がん剤HVJ-E （GEN0101/TSD-0014）の開発状況について anges.co.jp ↗ |
| 2011-06-15 | AnGes, Inc. | 子会社ジェノミディアとTSD Japan社がライセンス活動の共同実施に関する契約を締結 － GEN0101／TSD-0014のグローバル開発に向けたライセンス活動を強化 － anges.co.jp ↗ |
| 2011-06-13 | AnGes, Inc. | GEN0101/TSD-0014（HVJ-E）の医薬特許が成立（日本） －抗がん剤が対象－ anges.co.jp ↗ |
| 2008-10-28 | AnGes, Inc. | GEN0101のホルモン抵抗性前立腺がんに対する治療効果を確認 －第67回 日本癌学会学術総会で動物試験結果を発表－ anges.co.jp ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN0101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03818893 ↗ |
| Route | Other | “GEN0101 in a vial will be reconstituted with 1 mL of sterile distilled water and then will be injected intracutaneously” NCT03818893 ↗ |